bluebird bio, Inc. (NASDAQ:BLUE) Receives Consensus Rating of “Hold” from Brokerages

bluebird bio, Inc. (NASDAQ:BLUE) has been given an average rating of “Hold” by the nine ratings firms that are covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $49.14.

A number of equities research analysts have commented on the stock. JPMorgan Chase & Co. downgraded shares of bluebird bio from a “neutral” rating to an “underweight” rating in a research report on Friday, November 15th. StockNews.com began coverage on shares of bluebird bio in a research report on Friday, December 20th. They issued a “sell” rating for the company. Royal Bank of Canada reissued a “sector perform” rating and set a $80.00 price objective on shares of bluebird bio in a research report on Friday, November 15th. Barclays boosted their price objective on shares of bluebird bio from $2.00 to $40.00 and gave the company an “overweight” rating in a research report on Tuesday, December 31st. Finally, Bank of America downgraded shares of bluebird bio from a “buy” rating to a “neutral” rating and cut their price objective for the company from $60.00 to $10.00 in a research report on Friday, November 15th.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Regeneron Pharmaceuticals Inc. purchased a new position in shares of bluebird bio during the 4th quarter valued at $175,000. State Street Corp lifted its stake in shares of bluebird bio by 1.1% during the 3rd quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company’s stock valued at $1,996,000 after buying an additional 43,382 shares in the last quarter. SG Americas Securities LLC lifted its stake in shares of bluebird bio by 152.4% during the 3rd quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 74,185 shares in the last quarter. Captrust Financial Advisors lifted its stake in shares of bluebird bio by 48.2% during the 3rd quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company’s stock valued at $123,000 after buying an additional 77,293 shares in the last quarter. Finally, Verition Fund Management LLC purchased a new position in shares of bluebird bio during the 3rd quarter valued at $42,000. Hedge funds and other institutional investors own 87.43% of the company’s stock.

bluebird bio Trading Up 5.6 %

NASDAQ:BLUE opened at $6.39 on Thursday. The company has a current ratio of 0.51, a quick ratio of 0.33 and a debt-to-equity ratio of 0.37. bluebird bio has a 12 month low of $5.80 and a 12 month high of $38.40. The company has a market cap of $62.11 million, a PE ratio of -0.17 and a beta of 0.68. The company has a 50 day simple moving average of $8.17 and a two-hundred day simple moving average of $10.31.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.